Lance St. John Ho

Lance St. John Ho

Auto-generated profile, based on publicly available information

Lance St. John Ho

Biotechnology Innovation Centre, Rhodes University, South Africa

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

22 June 2020 in The Analyst
Verified
Journal Article
Closed access
PDF file
TFTamika Fellows
Tamika Fellows
LHLance Ho
Lance Ho
SFShane Flanagan
Shane Flanagan
RFRonen Fogel
Ronen Fogel
DODupe Ojo
Dupe Ojo
JLJanice Limson
Janice Limson
To decrease the burden of laborious and reagent-intensive screening of modified aptamers, their binding function requires assessment in assay formats compatible with the end diagnostic application. Here, we report on the use of an alternative and cost-effective approach: a rapid lateral flow assay (LFA) utilising streptavidin-conjugated gold nanoparticles (AuNP) as reporter molecules to screen novel ssDNA aptamers for their ability to detect CD4. Crossover-SELEX was employed to identify CD4-targeting aptamers from a ssDNA library enriched against a recombinant human CD4 protein (hCD4) conjugated to magnetic-beads and to endogenous CD4 expressed by U937 cells. Counter-selection with IgG-conjugated beads and CD4-negative Ramos RA-1 cells was employed. Following SELEX, four sequences (U4, U14, U20 and U26) were selected for candidate screening. Fluorescence confocal microscopy showed comparable localization of the Cy5-labeled aptamer U26, compared to antibodies binding CD4's cytoplasmic domain. Aptamer-hCD4 binding kinetics were evaluated by a qPCR-based magnetic-bead binding assay to unmodified aptamers. U26 exhibited the highest binding affinity (Kd = 2.93 ± 1.03 nM) to hCD4-conjugated beads. Citrate-stabilized gold nanoparticles (mean particle diameter, 10.59 ± 1.81 nm) were functionalized with streptavidin to allow immobilization of biotin-labeled aptamers. Except for U4, the aptamer–gold nanoparticle conjugates (Apt–AuNP) remained stable under physiological conditions with their size (approx. 15 nm) appropriate for use in the LFAs. Lateral-flow based screening was used to evaluate the suitability of the Apt–AuNPs as CD4-detecting reporter molecules by immobilizing hCD4 and flowing the nanoparticle conjugates across the LFA. Using this approach, two novel sequences were identified as being suitable for the detection of hCD4: visual detection at 9 min was obtained using U20 or U26. After 20 min, equivalent colorimetric hCD4 responses were observed between anti-CD4 monoclonal antibody (ΔI = 94.19 ± 3.71), an existing CD4 aptamer F1-62 (ΔI = 90.31 ± 19.31) and U26 (ΔI = 100.14 ± 14.61) LFA's, each demonstrating high specificity to hCD4 compared to IgG. From the above, Crossover-SELEX allowed for the successful identification of ssDNA aptamers able to detect hCD4. Streptavidin-conjugated AuNPs, when bound to candidate aptamers, show potential application here as screening tools for the rapid evaluation of aptamer performance in low-cost lateral flow diagnostics.

26 March 2019 in ACS Omega
Verified
Journal Article
Open access
LHLance St. John Ho
Lance St. John Ho
JLJanice L. Limson
Janice L. Limson
RFRonen Fogel
Ronen Fogel
Despite the widespread knowledge of the influence that electrode pretreatments have on electroanalysis, pretreatments of gold electrodes for impedimetric aptasensors remain study-specific. This may be a neglected reason behind the limited consensus in reports focusing on creation and testing of aptasensors. To investigate this, several commonly reported pretreatments were applied to gold electrodes that were subsequently used to fabricate thrombin-specific impedimetric aptasensors, which are widely reported in the literature. Layer-by-layer electrochemical impedance spectroscopy analyses were conducted to determine the effect the pretreatment selection has on impedimetric responses during fabrication and testing of the aptasensor. Pretreatments were evaluated using factors crucial for biosensor deployment: the repeatability of interelectrode measurements and whether biosensors produced statistically significant responses when exposed to 2 μM thrombin. Individual pretreatments were found to impart unique physicochemical properties to electrode surfaces, indicated by variations in measured capacitances (impedimetry) and electrode surface topographies (scanning electron microscopy). Impedimetrically measured resistivity (Rtotal) of electrodes increased during layering of the biosensor across all the investigated pretreatments: from 852 ± 830 Ω (bare electrodes) to 3117 ± 1199 Ω (fabricated aptasensors exposed to thrombin), consistent with prior literature. Crucially, the magnitude and reproducibility of Rtotal values measured during fabrication and testing of the assembled aptasensor were strongly contingent on the pretreatment. Depending on the pretreatment, interelectrode sensor responses exhibited relative standard deviations between 38 and 150%. These findings propose that the choice of gold-surface pretreatment protocols is an overlooked—yet crucial—factor to consider when developing analytically valid impedimetric aptasensors.

19 February 2021 in Analytical Methods
Verified
Journal Article
Open access
PDF file
SFShane Patrick Flanagan
Shane Patrick Flanagan
RFRonen Fogel
Ronen Fogel
Adrienne Lesley EdkinsAdrienne Lesley Edkins
Adrienne Lesley Edkins
LHLance St. John Ho
Lance St. John Ho
JLJanice Limson
Janice Limson
Most aptamers targeting cell-expressed antigens are intended for in vivo application, however, these sequences are commonly generated in vitro against synthetic oligopeptide epitopes or recombinant proteins. As these in vitro analogues frequently do not mimic the in vivo target within an endogenous environment, the evolved aptamers are often prone to nonspecific binding. The presence of dead cells and cellular debris further complicate aptamer targeting, due to their high nonspecific affinities to single-stranded DNA. Despite these known limitations, assessment of cell viability and/or the removal of dead cells is rarely applied as part of the methodology during in vivo testing of aptamer binding. Furthermore, the extent and route(s) by which dead cells uptake existing aptamers remains to be determined in the literature. For this purpose, the previously reported aptamer sequences 5TR1, 5TR4, 5TRG2 and S22 – enriched against the MUC1 tumour marker of the mucin glycoprotein family – were used as model sequences to evaluate the influence of cell viability and the presence of nontarget cell-expressed protein on aptamer binding to the MUC1 expressing human cancer cell lines MCF-7, Hs578T, SW480, and SW620. From fluorescence microscopy analysis, all tested aptamers demonstrated extensive nonspecific uptake within the nuclei of dead cells with compromised membrane integrities. Using fluorescent-activated cell sorting (FACS), the inclusion of excess double-stranded DNA as a blocking agent showed no effect on nonspecific aptamer uptake by dead cells. Further nonspecific binding to cell-membrane bound and intracellular protein was evident for each aptamer sequence, as assessed by southwestern blotting and FACS. These factors likely contributed to the ∼120-fold greater binding response of the 5TR1 aptamer to dead MCF-7 cells over equivalent live cell populations. The identification of dead cells and cellular debris using viability stains and the subsequent exclusion of these cells from FACS analysis was identified as an essential requirement for the evaluation of aptamer binding specificity to live cell populations of the cancer cell lines MCF-7, Hs578T and SW480. The research findings stress the importance of dead cell uptake and more comprehensive cell viability screening to validate novel aptamer sequences for diagnostic and therapeutic application.